Summary
The effects of sulfonylurea on glucagon secretion were characterized in the perfused rat pancreas using glibenclamide (1 μg/ml) or tolazamide (10 μg/ml) in the presence of 3.3 mmol/1 glucose. Glucagon release, which was unaffected by glibenclamide at 2.75 mmol/1 calcium, was suppressed at 1.19 and 0.64 mmol/l but transiently stimulated at 0.25 mmol/l extracellular calcium. The insulinogenic effect of glibenclamide at 0.64 and 0.25 mmol/1 calcium was enhanced by 35% and 89%, respectively, compared to the response at 2.75 mmol/1 calcium. The stimulatory effect of the compound on somatostatin secretion, however, was lost at the lower calcium levels. The effects of tolazamide at 2.75 and 0.64 mmol/1 calcium mimicked those of glibenclamide, thus indicating that our results with the latter compound may be representative for all sulfonylureas. In pancreata from insulin-deficient alloxan diabetic rats, glibenclamide completely lost its inhibitory effect on glucagon release at 0.64 mmol/1 calcium. Inhibition was not restored by adding insulin (25 U/1) to the perfusate. However, when diabetic rats had been treated with insulin for 6–7 days, glibenclamide suppressed glucagon release at low calcium levels in the absence of stimulated insulin and somatostatin release. It is concluded that, at low calcium concentrations, sulfonylureas suppress glucagon secretion by a direct action on the A cell and not through paracrine interactions by insulin and somatostatin. Prolonged insulin deficiency impairs the sulfonylurea action on glucagon secretion.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ipp E, Dobbs RE, Arimura A, Vale W, Harris V, Unger RH (1977) Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymine-cholecystokinin, and tolbutamide. J Clin Invest 60: 760–765
Samols E, Weir GC, Ramseur R, Day JA, Patel YC (1978) Modulation of pancreatic somatostatin by adrenergic and cholinergic agonism and by hyper- and hypoglycemic sulfonamides. Metabolism 27 (Suppl 1): 1219–1221
Efendić S, Enzmann F, Nylén A, Uvnas-Wallensten K, Luft R (1979) Effect of glucose/sulfonylurea interaction on release of insulin, glucagon and somatostatin from isolated perfused rat pancreas. Proc Natl Acad Sci USA 76: 5901–5904
Aguilar-Parada E, Eisentraut AM, Unger RH (1969) Effect of HB419 induced hypoglycemia on pancreatic glucagon secretion. Horm Metab Res 1 (Suppl): 48–50
Pek S, Fajans SS, Floyd JC, Knoph RF, Conn JW (1972) Failure of sulfonylureas to suppress plasma glucagon in man. Diabetes 21:216–222
Kajinuma H, Kuzuya T, Ide T (1974) Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs. Diabetes 23: 412–417
Loubatières AL, Loubatières-Mariani MM, Alric R, Ribes G (1974) Tolbutamide and glucagon secretion. Diabetologia 10: 271–276
Samols E, Harrison J (1976) Intraislet negative insulin-glucagon feedback. Metabolism 25 (Suppl 1): 1443–1447
Samols E, Tyler JM, Mialhe P (1969) Suppression of pancreatic glucagon release by the hypoglycemic sulfonylureas. Lancet 1: 174–176
Laube H, Fussganger R, Goberna K, Schröder K, Straub K, Sussman K, Pfeiffer EF (1971) Effects of tolbutamide on insulin and glucagon secretion of the isolated perfused rat pancreas. Horm Metab Res 3: 238–242
Ohneda A, Sato M, Matsuda K, Itabashi H, Horigome K, Chiba M, Yamagata S (1974) Suppression of pancreatic glucagon secretion by tolbutamide in dogs. Horm Metab Res 6: 478–482
Grodsky GM, Epstein GH, Fanska R, Karam JH (1977) Pancreatic action of the sulfonylureas. Fed Proc 36: 2714–2719
Luyckx AS (1983) Pharmacologic compounds affecting glucagon secretion. In: Lefèbvre PJ (ed) Glucagon II. Handbook of experimental pharmacology, Vol 66/II. Springer, Berlin Heidelberg New York, pp 175–177
Kadowaki S, Taminato T, Chiba T, Nozawa M, Fujita T, Norman AW (1983) Effect of tolbutamide on insulin, glucagon and somatostatin release from the diabetic rat pancreas with special reference to glucose concentration. Endocrinology 122: 2187–2192
Efendić S, Enzmann F, Nylén A, Uvnas-Wallensten K, Luft R (1980) Sulphonylurea (glibenclamide) enhances somatostatin and inhibits glucagon release induced by arginine. Acta Physiol Scand 108: 231–233
Efendić S, Grill V, Nylén A, Ostenson C-G (1982) Difference in calcium dependendy of insulin, glucagon and somatostatin secretion in response to glibenclamide in perfused rat pancreas. Diabetologia 22: 475–479
Grill V, Nylén A, Ostenson C-G, Efendić S (1984) Glibenclamide stimulates and glucose inhibits glucagon release induced by calcium deprivation. Diabetes 33: 505–509
Östenson C-G, Grill V, Nylén A, Efendić S (1983) Modulation by IBMX, fasting and experimental diabetes of glibenclamide-induced islet hormone release from the perfused rat pancreas. Diabète et Métabolisme 9: 58–65
Rasch R (1979) Control of blood glucose levels in the streptozotocin diabetic rat using a long-acting heat-treated insulin. Diabetologial 16: 185–190
Loubatières AL, Mariani MM, Ribes G, DeMalbosc H, Chapal J (1969) Etude expérimentale d'un nouveau sulfamide hypoglycíant particulièrement actif, le HB 419 ou glibenclamide. Diabetologia 5: 1–10
Umbreit WW, Burris RH, Stauffer JF (1957) In: Manometric techniques, vol 1. Burgess, Minneapolis, p 149
Herbert V, Lau KS, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375–1384
Faloona GR, Unger RH (1974) Radioimmunoassay technique. In: Jaffe BM and Behrman HE (eds) Methods of hormone radioimmunoassay, vol 1. Academic, New York, pp 324–326
Frankel BJ, Heldt AM, Grodsky GM (1982) Effects of K+ and arginine on insulin, glucagon, and somatostatin release from the in vitro perfused rat pancreas. Endocrinology 110: 428–431
Östenson C-G (1980) Aloxan reversibly impairs glucagon release and glucose oxidation by pancreatic A2-cells. Biochem J 188: 201–206
Goto Y, Berelowitz M, Frohman LA (1981) Acute effects of alloxan and streptozotocin-induced insulin deficiency on somatostatin and glucagon secretion by the perfused isolated rat pancreaticoduodenal preparation. Diabetologia 20: 66–71
Grill V, Efendić S (1984) Abnormal D cell secretion in alloxandiabetes: influence by drug and aberrant metabolism. Am J Physiol 246: E483-E492
Pagliara AS, Stillings SN, Haymond MW, Hover BA, Matschinsky FM (1975) Insulin and glucose as modulators of the aminoacid-induced glucagon release in the isolated pancreas of alloxan and streptozotocin diabetic rats. J Clin Invest 55: 244–255
Matschinsky FM, Pagliara AS, Hover BA, Pace CS, Ferrendelli JA, Williams A (1976) Hormone secretion and glucose metabolism in islets of Langerhans of the isolated perfused pancreas from normal and streptozotocin diabetic rats. J Biol Chem 251: 6053–6061
Unger R, Aguilar-Parada E, Muller W, Eisentraut A (1970) Studies of alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837–848
Gerich JE (1983) Glucose in the control of glucagon secretion. In: Lefèbvre PJ (ed) Glucagon II. Handbook of experimental pharmacology, vol 66/II. Springer, Berlin Heidelberg New York, pp 4–18
Hellerström C (1977) Growth pattern of pancreatic islets in animals. In: Volk BW, Wellman KF (eds) The diabetic pancreas. Plenum, New York, pp 61–97
Gylfe E, Hellman B, Sehlin J, Täljedahl I-B (1984) Interaction of sulfonylurea with the pancreatic B-cell. Experentia 40: 1126–1134
Lundqvist I, Fanska R, Grodsky GM (1976) Interaction of calcium and glucose on glucagon secretion. Endocrinology 99: 1304–1312
Leclercq-Meyer V, Marchand J, Malaisse WJ (1976) The role of calcium in glucagon release, interactions between glucose and calcium. Diabetologia 12: 531–538
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Östenson, C.G., Nylén, A., Grill, V. et al. Sulfonylurea-induced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct, non-paracrine effect. Diabetologia 29, 861–867 (1986). https://doi.org/10.1007/BF00870141
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00870141